6 July 2018
McCann FitzGerald advises Boston Scientific Corp. on Irish aspects of its acquisition of Cryterion Medical, Inc.
We advised Boston Scientific Corp. on the Irish aspects of its acquisition of Cryterion Medical, Inc. a private company developing a single-shot cryoablation platform for the treatment of atrial fibrillation, the most common form of heart arrhythmia. Cryterion Medical Ireland, Limited, a manufacturing subsidiary of Cryterion Medical, Inc., was included in the merger.
Boston Scientific has been an investor in Cryterion since its inception in 2016 and the transaction price for the approximately 65% remaining stake was $202 million in up-front cash.
The acquisition of this cryoballoon platform positions the Boston Scientific Corp. as the first corporation to have both cryothermal and radiofrequency single-shot, balloon-based ablation therapies in its portfolio.